Elekta AB (publ) (EKTA-B.ST) Research

Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Versa HD, tailored for brain metastases; the groundbreaking Elekta Unity, leveraging MR-Linac technology; linear accelerators like Elekta Harmony; and Elekta Infinity, designed to address diverse radiotherapy needs. The company also provides Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy. Beyond primary treatment devices, Elekta supplies comprehensive treatment management solutions, automated and integrated quality assurance tools, and hardware/software for motion management. Specialized oncology platforms feature MOSAIQ Plaza for multidisciplinary cancer care, the managed hosting service Elekta Axis Cloud, and Elekta Studio for image-guided brachytherapy. Complementary hardware includes the ImagingRing mobile CT scanner. For brachytherapy, they offer smart tools like Oncentra Brachy to streamline repetitive tasks, alongside applicators such as Venezia and Geneva for cervical cancer treatment, and the Elekta Flexitron afterloader for precise workflow execution. In the field of neurosurgery and radiosurgery, Elekta provides the Leksell Gamma Knife series, including Icon for personalized radiation treatment, Perfexion as a vital tool for neurosurgeons, and Lightning for accelerated radiosurgery. Their neurosurgery product line further encompasses the Leksell Vantage Stereotactic System for intracranial procedures and the Leksell Stereotactic System for minimally invasive interventions. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.

Open Elekta AB (publ) (EKTA-B.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.